Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.
The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. The short- and long-term metabolic safety of sertindole was compared to that of risperidone in a subset of patients enrolled in the sertindole cohort prospective (SCoP) study, an open randomized study. In 261 randomized patients, there were moderate increases in mean weight, BMI, and waist circumference during treatment with either sertindole or risperidone; after 12 weeks, the increase in weight was 1.3 and 1.1 kg, respectively, and after 36 weeks, it was 2.2 and 2.0 kg, respectively. From baseline to last assessment (up to 60 weeks), weight gains of 1.8 and 1.7 kg for sertindole and risperidone, respectively, were observed. Similar proportions of patients (sertindole: 17% versus risperidone: 16%) had weight increases ≥7% from baseline to last assessment. The mean changes from baseline in triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, plasma glucose and blood pressure were small and not clinically relevant in both treatment groups. No patient in either of the groups developed type 2 diabetes during the study. At last assessment, the prevalence of metabolic syndrome (International Diabetes Federation) was 17% in the sertindole group and 26% in the risperidone group and the incidence of metabolic syndrome was 7% in the sertindole group and 10% in the risperidone group. Treatment with either sertindole or risperidone did not appear to be associated with an increased comparative risk of developing metabolic syndrome. In general, the metabolic effects of sertindole and risperidone were similar.
De Hert
Marc
M
University Psychiatric Center Catholic University Leuven, UPC KUL campus Kortenberg, Leuvensesteenweg 517, Kortenberg, Belgium. marc.de.hert@uc-kortenberg.be
Mittoux
Aurélia
A
He
Yuan
Y
Peuskens
Joseph
J
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D016009:Chi-Square Distribution; D005215:Fasting / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000209:etiology*; D008875:Middle Aged; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D012737:Sex Factors; D013997:Time Factors; D055105:Waist Circumference / Q000187:drug effects; D055815:Young Adult
D014150:Antipsychotic Agents; D001786:Blood Glucose; D007093:Imidazoles; D007211:Indoles; D008055:Lipids; C066304:sertindole; D018967:Risperidone
Int J Clin Pract. 2007 Aug;61(8):1356-70
17627711
Schizophr Res. 2008 Oct;105(1-3):175-87
18775645
Am Heart J. 2005 Dec;150(6):1115-21
16338246
Diabetes Care. 2001 Apr;24(4):683-9
11315831
Schizophr Res. 2005 Dec 1;80(1):45-53
16198088
CNS Drugs. 2005;19 Suppl 1:1-93
15998156
Schizophr Res. 2005 Nov 15;79(2-3):281-8
15964743
J Clin Psychiatry. 2004;65 Suppl 7:4-18; quiz 19-20
15151456
J Clin Psychopharmacol. 2004 Oct;24(5 Suppl 1):S1-6
15356414
Schizophr Res. 2010 Mar;117(1):68-74
20060684
Diabetes Metab. 2007 Jun;33(3):169-75
17412628
Schizophr Res. 2000 Sep 29;45(1-2):21-8
10978869
Lancet. 2009 Aug 22;374(9690):620-7
19595447
Arch Gen Psychiatry. 2007 Oct;64(10):1123-31
17909124
Schizophr Res. 2006 Sep;86(1-3):15-22
16884895
Acta Psychiatr Scand. 2010 Nov;122(5):345-55
20384598
Int J Psychiatry Clin Pract. 2002;6(1):27-32
24931887
J Psychopharmacol. 2007 Jun;21(4):357-73
17656425
J Am Coll Cardiol. 2005 Jul 5;46(1):173-5
15992653
Eur Arch Psychiatry Clin Neurosci. 2010 Feb;260(1):59-68
19455275
Eur Psychiatry. 2009 Sep;24(6):412-24
19682863
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):804-11
17551996
Clin Pract Epidemiol Ment Health. 2006 Jun 27;2:14
16803620
Acta Psychiatr Scand. 2009 Jan;119(1):4-14
19133915
J Psychiatr Res. 2009 Sep;43(13):1106-11
19398113
Schizophr Res. 2008 Apr;101(1-3):273-86
18258416
Lancet. 2009 Jan 3;373(9657):31-41
19058842
Am J Psychiatry. 2009 Feb;166(2):152-63
19015230
Acta Psychiatr Scand. 2007 Nov;116(5):317-33
17919153
Am J Manag Care. 2007 Nov;13(7 Suppl):S170-7
18041878
Am J Psychiatry. 2004 Aug;161(8):1334-49
15285957
Pharmacoepidemiol Drug Saf. 2008 May;17(5):425-33
18384186
Diabetes Care. 2004 Feb;27(2):596-601
14747245
Schizophr Res. 2009 Aug;113(1):1-11
19524406
J Clin Psychiatry. 2008 Apr;69(4):514-9
18370570
Int Clin Psychopharmacol. 2006 Mar;21 Suppl 2:S11-5
16601508
BMJ. 2000 Aug 19-26;321(7259):483-4
10948028
Int J Psychiatry Clin Pract. 2000;4(1):47-54
24927312
Expert Opin Pharmacother. 2006 Sep;7(13):1825-34
16925508
Am J Psychiatry. 1997 Jun;154(6):782-91
9167505
JAMA. 2001 May 16;285(19):2486-97
11368702
J Clin Psychiatry. 2009 Jul;70(7):1041-50
19653979
J Clin Psychiatry. 2006 Oct;67(10):1493-500
17107239
Arch Gen Psychiatry. 2009 Jul;66(7):713-20
19581562
Diabet Med. 2006 May;23(5):469-80
16681555
Schizophr Res. 2008 Apr;101(1-3):295-303
18299188
Circulation. 2005 Oct 25;112(17):2735-52
16157765
Lancet. 2004 Sep 11-17;364(9438):937-52
15364185
World Psychiatry. 2009 Feb;8(1):15-22
19293950
Am J Psychiatry. 2009 Mar;166(3):345-53
19147694
Br J Psychiatry. 2008 Jun;192(6):406-11
18515889